SSY Group

SSY Group Limited, established in 2004, is a prominent pharmaceutical manufacturer based in China, boasting nearly seven decades of operational history and a strong brand reputation. The company achieved public listing on the Hong Kong Stock Exchange in December 2005, trading under the ticker HKEX: 2005. SSY Group is a key player in the Healthcare and Pharmaceuticals sectors, recognized for its extensive experience and market presence. Its strategic focus encompasses the research, development, manufacturing, and sale of a diverse portfolio of pharmaceutical products.

The Group's core business activities include the production of Over-The-Counter (OTC) drugs, bulk medicine, and essential medical materials, with a particular emphasis on intravenous infusion solutions supplied to hospitals and distributors. SSY Group operates manufacturing facilities in Hebei Province and Jiangsu Province, China, positioning its products as leaders within the high-end hospital market. With an employee range of 5,000 - 10,000 individuals, the company maintains a significant operational footprint. Interested parties can Meet SSY Group's team to understand the leadership driving its success.

Since June 2018, SSY Group has been recognized as a component stock of the Morgan Stanley Capital International Index (MSCI) China Index, underscoring its importance in the regional financial landscape. The company generates substantial revenue, reported at $827.5M. Its commitment to quality and innovation in pharmaceutical manufacturing solidifies its leading position in the Chinese healthcare market.